Necroptosis (or ‘programmed necrosis’) is a caspase‐independent cell death pathway that operates downstream of death receptors, including Tumour Necrosis Factor Receptor‐1 (TNFR1), and the Toll‐like receptors, TLR3 and TLR4. Owing to its immunogenicity, necroptosis has been attributed roles in the pathogenesis of several diseases, including inflammatory bowel disease and the tissue damage arising from ischaemic‐reperfusion injuries. Only over the past 7 years has the core machinery of this pathway, the receptor‐interacting protein kinase‐3 (RIPK3) and the pseudokinase, Mixed Lineage Kinase domain‐Like (MLKL), been defined. Our current understanding of the pathway is that RIPK3‐mediated phosphorylation activates cytoplasmic MLKL, which is the most terminal known effector in the pathway, leading to MLKL's oligomerisation, translocation to, and permeabilisation of, the plasma membrane. Here, we discuss the insights gleaned from structural and biophysical studies of MLKL and highlight the known unknowns surrounding MLKL's mechanism of action and activation.